New Products In Brief
This article was originally published in The Gray Sheet
Executive SummaryJ&J/DePuy’s Trumatch
You may also be interested in...
Cancer Genetics plans initial public offering. Mitralign raises $35 million for valve repair device. More financings.
A drug-eluting stent and prostate cancer assay are among newly approved devices.